Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours

被引：0
|
作者：
Lu, S. [1 ]
De Braud, F. G. M. [2 ]
Fan, Y. [3 ]
Hu, X. [4 ]
Ohe, Y. [5 ]
Yu, Y. [6 ]
Ahn, M-J. [7 ]
Cassier, P. [8 ]
Lin, J. J. [9 ]
Paz-Ares, L. [10 ]
Xue, C. [11 ]
Bordogna, W. [12 ]
Patel, S. [13 ]
Zeuner, H. [12 ]
Dong, X. [14 ]
机构：
[1] Shanghai Jiao Tong Univ, Dept Med Oncol, Shanghai Chest Hosp, Shanghai, Peoples R China
[2] Univ Milan, Med Oncol & Haematol Dept, Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[3] Zhejiang Canc Hosp, Dept Med Thorac Oncol, Hangzhou, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[5] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[6] Harbin Med Univ Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[7] Sungkyunkwan Univ, Sch Med, Dept Med, Seoul, South Korea
[8] Ctr Leon Berard, Dept Med, Lyon, France
[9] Massachusetts Gen Hosp, Ctr Thorac Canc, Boston, MA USA
[10] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain
[11] F Hoffmann La Roche Ltd, Biostat, Mississauga, ON, Canada
[12] F Hoffmann La Roche Ltd, Prod Dev Med Affairs, Basel, Switzerland
[13] Genentech Inc, Prod Dev Oncol, South San Francisco, CA USA
[14] Huazhong Univ Sci & Technol, Canc Ctr, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1852
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
666P
引用
收藏
页码：S468 / S469
页数：2
相关论文
共 50 条
  • [31] Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK plus ) metastatic/locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice
    Demetri, G. D.
    Peters, S.
    Hibbar, D. P.
    Davies, J.
    Maund, S. L.
    Veronese, L.
    Liu, H.
    Humblet, O.
    Perez, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S399 - S399
  • [32] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: of response by line of therapy
    Liu, S. V.
    De Braud, F.
    Drilon, A.
    Doebele, R. C.
    Patel, M. R.
    Cho, B. C.
    Ahn, M-J.
    Chiu, C-H.
    Farago, A. F.
    Goto, K.
    Lee, J.
    Ohe, Y.
    Ou, S-H. I.
    Cassier, P.
    Tan, D. S. W.
    Otterson, G. A.
    Veronese, L.
    Osborne, S.
    Simmons, B.
    Siena, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S472 - S473
  • [33] Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
    Doebele, R.
    Ahn, M.
    Siena, S.
    Drilon, A.
    Krebs, M.
    Lin, C.
    De Braud, F.
    John, T.
    Tan, D.
    Seto, T.
    Dziadziuszko, R.
    Arkenau, H.
    Barlesi, F.
    Rolfo, C.
    Wolf, J.
    Chow-Maneval, E.
    Multani, P.
    Cui, N.
    Riehl, T.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S321 - S322
  • [34] Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases
    Paz-Ares, L.
    Dziadziuszko, R.
    Drilon, A.
    John, T.
    Krebs, M.
    Demetri, G.
    Shaw, A.
    Siena, S.
    Wolf, J.
    Farago, A.
    Simmons, B.
    Ye, C.
    Huang, X.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S305 - S305
  • [35] Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors or ROS1-Positive NSCLC with CNS Metastases
    Paz-Ares, Luis
    Dziadziuszko, Rafal
    Drilon, Alexander
    John, Thomas
    Krebs, Matthew
    Demetri, George
    Shaw, Alice T.
    Siena, Salvatore
    Wolf, Juergen
    Farago, Anna F.
    Simmons, Brian
    Pitcher, Bethany
    Huang, Xinhui
    Doebele, Robert
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 235 - 235
  • [36] A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets).
    Dingemans, Anne-Marie C.
    Griesinger, Frank
    Paz-Ares, Luis
    Perol, Maurice
    Ren, Shengxiang
    Hoglander, Elen
    Kurtsikidze, Nino
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
    Demetri, G. D.
    Paz-Ares, L.
    Farago, A. F.
    Liu, S. V.
    Chawla, S. P.
    Tosi, D.
    Kim, E. S.
    Blakely, C. M.
    Krauss, J. C.
    Sigal, D.
    Bazhenova, L.
    John, T.
    Besse, B.
    Wolf, J.
    Seto, T.
    Chow-Maneval, E.
    Multani, P. S.
    Johnson, A.
    Simmons, B.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2018, 29 : 175 - 175
  • [38] Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
    Dziadziuszko, R.
    Siena, S.
    Tan, D. S. W.
    Cho, B. C.
    Ahn, M-J.
    Goto, K.
    Garrido-Lopez, P.
    Farago, A. F.
    Loong, H. H. F.
    Tosi, D.
    John, T.
    Wolf, J.
    Chiu, C-H.
    Liu, S. V.
    Patel, M. R.
    Drilon, A.
    Pitcher, B.
    Simmons, B.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S833 - S834
  • [39] Clinical and analytic validation of FoundationOne CDx™ for NTRK fusion-positive solid tumors in patients treated with entrectinib
    Fabrizio, David
    Milbury, Coren
    Yip, Wai-Ki
    Yilmazel, Bahar
    Bai, Xiaobo
    Liao, Juan
    Smith, David
    Burns, Christine
    Vietz, Christine
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [40] Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Rolfo, C.
    Dziadziuszko, R.
    Doebele, R. C.
    Demetri, G.
    Simmons, B.
    Huang, X.
    Ye, C.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30
12345